PKU GOLIKE: the evolution in the nutritional management for Phenylketonuria
is a brand-new product line of food for special medical purposes (FSMP) for a real change in the dietary management of Phenylketonuria (PKU)
consists in a Phe-free amino acid mix in coated granules, developed by applying a patented pharmaceutical technology, the Physiomimic Technology™
, to an FSMP.
With the ambition of improving health and quality of life of people living and dealing with PKU the coated granules provide PKU GOLIKE
with unique benefits:
The innovation and benefits of PKU GOLIKE products lie in the granule formulation, which is the basis of all the options in the PKU GOLIKE family.
The granules make PKU GOLIKE different from all other PKU products, which generally dissolve in water.
It can take time to get used to a different format and texture, but it is right because granules remain intact during consumption that you don’t perceive the amino acid taste, odour or aftertaste. Granules break down gradually only during digestion allowing a prolonged release of amino acids and a more physiological absorption in line with natural proteins.1,2
The PKU GOLIKE Family: all the products for PKU nutritional management
The PKU GOLIKE
range consists of different formats to satisfy PKU patients’ needs.
Please refer to your doctor or your medical centre to discuss daily doses, depending on age, bodyweight, medical condition and any special conditions (e.g. pregnancy and breastfeeding).
PKU GOLIKE products must be used under medical supervision.
- Scheinin M, et al. Amino acid plasma profiles from a prolonged-release protein substitute for phenylketonuria: a randomised, single-dose, four-way crossover trial in healthy volunteers. Nutrients. 2020;12(6):1653.
- Giarratana N et al. A New Phe-Free Protein Substitute Engineered to Allow a Physiological Absorption of Free Amino Acids for Phenylketonuria. 2018. Journal of Inborn Errors of Metabolism & Screening.
- Daly A, et al. Protein substitutes in PKU; their historical evolution. Nutrients. 2021;13(2):484.